SCHEMBL21756591

SCHEMBL21756591

Cc1cccc([N+](=O)[O-])c1Nc1ccc(Br)cn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
POLB P06746 1/20 0.53
PKM P14618 1/20 0.53
LMNA P02545 4/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
RAB9A P51151 3/20 0.44
NPC1 O15118 2/20 0.44
TP53 P04637 1/20 0.44
MAPK1 P28482 1/20 0.44
TSHR P16473 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KCNMA1 Q12791 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MAPT P10636 5/20 0.41
XBP1 P17861 1/20 0.41
PPARG P37231 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31047222 1.00 KMT2A (0.53) KMT2AMEN1POLBPKMLMNA
SCHEMBL15412383 0.84 TSHR (0.45) KMT2AMEN1POLBPKMCYP1A2
SCHEMBL21386623 0.83 RAB9A (0.51) KMT2AMEN1PKMLMNARAB9A
SCHEMBL21756588 0.82 SMN1; SMN2 (0.41) KMT2AMEN1LMNARAB9ANPC1
SCHEMBL31220844 0.80 MAPT (0.62) KMT2AMEN1LMNACYP1A2CYP2C19
SCHEMBL3911920 0.79 TSHR (0.49) KMT2AMEN1PKMLMNARAB9A
SCHEMBL31047229 0.79 TSHR (0.49) KMT2AMEN1PKMLMNARAB9A
SCHEMBL21756603 0.79 RAB9A (0.39) KMT2AMEN1POLBPKMLMNA
SCHEMBL27143115 0.78 TSHR (0.45) KMT2AMEN1CYP1A2CYP2C19TSHR
SCHEMBL9995235 0.78 KMT2A (0.61) KMT2AMEN1POLBPKMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11008292-B2 FGFR4 inhibitor and preparation method and use thereof GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2021-05-18 US disclosed
US-20200062716-A1 FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2020-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11008292-B2 FGFR4 inhibitor and preparation method and use thereof FGFR4, FGFR1, FGFR2 KMT2A 2244/4885MEN1 1696/4885POLB 4242/4885
US-20200062716-A1 FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF FGFR4, FGFR1, FGFR2 KMT2A 2244/4885MEN1 1696/4885POLB 4242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.